{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:21:05Z","timestamp":1786119665998,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1097\/mjt.0b013e3181e9b655","type":"journal-article","created":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T05:52:51Z","timestamp":1333605171000},"page":"281-286","source":"Crossref","is-referenced-by-count":4,"title":["Application of Botulinum Toxin to Clinical Therapy"],"prefix":"10.1097","volume":"19","author":[{"given":"Norman S.","family":"Levy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David T.","family":"Lowenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"Suppl 4","key":"R1-7-20210202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-1331.2006.01648.x","article-title":"The structure and mode of action of different botulinum neurotoxins.","volume":"13","author":"Dolly","year":"2006","journal-title":"Eur J Neurol"},{"key":"R2-7-20210202","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000060669","article-title":"Botulinum toxin: from poison to pharmaceutical. The history of a poison that became useful to mankind.","volume":"30","author":"Kreyden","year":"2002","journal-title":"Curr Probl Dermatol"},{"issue":"Suppl 1","key":"R3-7-20210202","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","article-title":"Immunological aspects of Botox, Dysport and MyoblocNeuroBloc.","volume":"13","author":"Dressler","year":"2006","journal-title":"Eur J Neurol"},{"key":"R4-7-20210202","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.2174\/138161209789271843","article-title":"Current clinical applications of botulinum toxin.","volume":"15","author":"Truong","year":"2009","journal-title":"Current Pharmaceutical Design"},{"key":"R5-7-20210202","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.clindermatol.2003.11.003","article-title":"History of the clinical use of botulinum toxin A and B.","volume":"21","author":"Carruthers","year":"2003","journal-title":"Clin Dermatol"},{"key":"R6-7-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-2004-830901","article-title":"Botulism: update and review.","volume":"24","author":"Cherington","year":"2004","journal-title":"Semin Neurol"},{"key":"R7-7-20210202","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/0003-4819-129-3-199808010-00011","article-title":"Botulism in the United States: a clinical and epidemiologic review.","volume":"129","author":"Shapiro","year":"1998","journal-title":"Ann Intern Med"},{"key":"R8-7-20210202","first-page":"1","article-title":"Ueber einen neuen anaeroben Bacillus und seine Beziehungen zum Botulismus.","volume":"26","author":"van Ermengem","year":"1897","journal-title":"Zeitschrift fur Hyg und Infektionskr-ankheiten"},{"key":"R9-7-20210202","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1076\/0964-704X(200008)9:2;1-Y;FT218","article-title":"On the first systematic descriptions of botulism and botulinum toxin by Justinus Kerner (1786-1862).","volume":"9","author":"Erbguth","year":"2000","journal-title":"J Hist Neurosci"},{"key":"R10-7-20210202","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jama.285.8.1059","article-title":"; Working Group on Civilian Biodefense. Botulinum toxin as a biological weapon: medical and public health management.","volume":"285","author":"Arnon","year":"2001","journal-title":"JAMA"},{"key":"R12-7-20210202","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1590\/S0004-282X2005000100035","article-title":"Botulinum toxin: mechanisms of action.","volume":"63","author":"Dressler","year":"2005","journal-title":"Arq Neuropsiquiatr"},{"key":"R13-7-20210202","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1152\/ajplegacy.1963.205.6.1213","article-title":"Sperelakis N (technical assistance of Levy NS). Transmembrane potential of trypsin-dispersed chick heart cells cultured in vitro.","volume":"205","author":"Lehmkuhl","year":"1963","journal-title":"Am J Physiol"},{"key":"R14-7-20210202","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","article-title":"The origin, structure and pharmacologic activity of botulinum toxin.","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharmacol Rev"},{"key":"R15-7-20210202","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1504\/TBJ.2008.018951","article-title":"How do the botulinum neurotoxins block neurotransmitter release: from botulism to the molecular mechanism of action.","volume":"1","author":"Poulain","year":"2008","journal-title":"The Botulinum Journal"},{"key":"R16-7-20210202","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/157340607781024438","article-title":"Botulinum toxin: pharmacology and clinical developments: a literature review.","volume":"3","author":"Hackett","year":"2007","journal-title":"Med Chem"},{"issue":"Suppl 6","key":"R17-7-20210202","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1093\/ajhp\/61.suppl_6.S5","article-title":"Pharmacology of botulinum neurotoxin serotype A.","volume":"61","author":"Wenzel","year":"2004","journal-title":"Am J Health Syst Pharm"},{"key":"R18-7-20210202","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","article-title":"From poison to remedy: the chequered history of botulinum toxin.","volume":"115","author":"Erbguth","year":"2008","journal-title":"J Neural Transm"},{"key":"R19-7-20210202","first-page":"924","article-title":"Pharmacologic weakening of extraocular muscles.","volume":"12","author":"Scott","year":"1973","journal-title":"Invest Ophthalmol"},{"key":"R20-7-20210202","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"key":"R21-7-20210202","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus.","volume":"79","author":"Scott","year":"1981","journal-title":"Trans Am Ophthalmol"},{"key":"R22-7-20210202","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1080\/09638280701607433","article-title":"Development of botulinum toxin.","volume":"29","author":"Scott","year":"2007","journal-title":"Disabil Rehabil"},{"key":"R23-7-20210202","doi-asserted-by":"crossref","first-page":"464","DOI":"10.12968\/hosp.2003.64.8.2260","article-title":"Botulinum toxin and the eye.","volume":"64","author":"Marsh","year":"2003","journal-title":"Hosp Med"},{"key":"R24-7-20210202","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0039-6257(01)00227-2","article-title":"Clostridium botulinum and the ophthalmologist: a review of botulism, including biological warfare ramifications of botulinum toxin.","volume":"46","author":"Caya","year":"2001","journal-title":"Surv Ophthalmol"},{"key":"R25-7-20210202","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1002\/(SICI)1097-4598(1997)6+<129::AID-MUS9>3.0.CO;2-B","article-title":"Botulinum toxin: historical perspective and potential new indications.","volume":"6","author":"Jankovic","year":"1997","journal-title":"Muscle Nerve"},{"key":"R26-7-20210202","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/mus.20033","article-title":"Botulinum toxins in neurological disease.","volume":"29","author":"Comella","year":"2004","journal-title":"Muscle Nerve"},{"key":"R27-7-20210202","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.parkreldis.2006.06.002","article-title":"Botulinum toxin: clinical use.","volume":"12","author":"Truong","year":"2006","journal-title":"Parkinsonism and Related Disorders"},{"key":"R28-7-20210202","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.toxicon.2008.11.013","article-title":"Disease-oriented approach to botulinum toxin use.","volume":"54","author":"Jankovic","year":"2009","journal-title":"Toxicon"},{"key":"R29-7-20210202","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2007.01.009","article-title":". North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.","volume":"56","author":"Lowe","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R30-7-20210202","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/hed.20247","article-title":"Botulinum toxinphysiology and applications in head and neck disorders.","volume":"27","author":"Keir","year":"2005","journal-title":"Head Neck"},{"key":"R31-7-20210202","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0302-2838(03)00250-1","article-title":"Botulinum toxin as a new therapy option for voiding disorders: current state of the art.","volume":"44","author":"Leippold","year":"2003","journal-title":"Eur Urol"},{"key":"R33-7-20210202","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2174\/157488606777934431","article-title":"The possible adverse effects of intramuscular botulinum toxin injections and their management.","volume":"1","author":"Bakheit","year":"2006","journal-title":"Curr Drug Saf"},{"key":"R34-7-20210202","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2005.06.011","article-title":". Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.","volume":"53","author":"Cote","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"R35-7-20210202","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1001\/jama.296.20.2476","article-title":". Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation.","volume":"296","author":"Chertow","year":"2006","journal-title":"JAMA"},{"key":"R36-7-20210202","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3129\/i07-123","article-title":"Retinal tear and raised intraocular pressure following unintentional intraocular botulinum toxin type A injection.","volume":"42","author":"Leung","year":"2007","journal-title":"Can J Ophthalmol"},{"key":"R39-7-20210202","first-page":"299","article-title":"MMWR Morbid Mortal Wkly Rep.","volume":"59","year":"2010","journal-title":""}],"container-title":["American Journal of Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00045391-201207000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:50:39Z","timestamp":1786042239000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00045391-201207000-00007"}},"subtitle":["Advances and Cautions"],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mjt.0b013e3181e9b655","relation":{},"ISSN":["1075-2765"],"issn-type":[{"value":"1075-2765","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}